2022: The future of pharma R&D is a connected technology ecosystem

The future of pharmaceutical R&D is increasingly reliant on a connected technology ecosystem, driven by trends such as digitization and decentralization, which have accelerated over the past few years. This shift has prompted life sciences organizations to adopt decentralized clinical trials and hybrid work environments, affecting major cost areas like real estate and R&D spending. The proliferation of R&D applications, resulting from acquisitions and the need for innovation, has led to complex IT portfolios and redundancies, which Box addresses with its Intelligent Content Management platform. This platform offers a unified, secure solution for managing content across various applications, aiding in compliance and reducing regulatory burdens through Box GxP Validation. By enabling a best-of-breed technology stack, Box facilitates seamless integration of SaaS applications, promoting innovation and cost control. As organizations adapt to this new normal, they must decide which innovations to maintain, balancing coopetition and innovation to manage rising R&D costs effectively.

No tracked trend matches for this post yet.

Use this post, company, and trend context to find content marketing opportunities, perform competitive analysis, or address product feature gaps via the Plushcap MCP server or the Plushcap API.